Newsletter
![Q1 and Not Done](https://usercontent.one/wp/www.epicentrx.com/wp-content/uploads/2024/04/Q42-1080x675.jpg?media=1721163528)
Q1 and Not Done
This being a leap year, EpicentRx leapt into action in Q1. In January, which is named after the two-faced Roman God, Janus, who focused...
![The Drive to ‘25](https://usercontent.one/wp/www.epicentrx.com/wp-content/uploads/2024/01/Epicentrx_Q4-newsletter_graphics_Race-to-2025-1080x675.jpg?media=1721163528)
The Drive to ‘25
The drive to 2025 is underway! With 2023 in the rear-view mirror, we at EpicentRx look ahead not only to 2024 but also to 2025 when we expect...
![No “Fall” in Activity for EpicentRx After Summer](https://usercontent.one/wp/www.epicentrx.com/wp-content/uploads/2023/11/fallimg-1080x675.jpg?media=1721163528)
No “Fall” in Activity for EpicentRx After Summer
A busy Fall “leaves” little to no downtime for EpicentRx Summer slowdown? What summer slowdown? EpicentRx kicked off the Fall season in high gear...
![Q2 Highlights from ASCO, BIO and beyond](https://usercontent.one/wp/www.epicentrx.com/wp-content/uploads/2021/10/default-980x653-1.jpg?media=1721163528)
Q2 Highlights from ASCO, BIO and beyond
As you may have noticed, EpicentRx is a company on the move. From the award of FDA Fast Track status for RRx-001 as an anti-oral mucositis agent to...